Get a free cooler bag with your Tandem t:slim X2TM insulin pump!§
Ready to simplify your diabetes management?
Now's the perfect time!
For a limited time, order a Tandem t:slim X2 insulin pump and receive a FREE branded cooler bag. Keep your supplies cool and organised on the go with this exclusive offer!
T&C's apply.§
†CGM sold separately
The t:slim X2™ insulin pump with Control-IQ™ technology can be used as a stand alone pump, or can be integrated with the Dexcom G7 or G6 continuous glucose monitoring (CGM)† system to activate the predictive insulin delivery technology.
The Control‑IQ advanced hybrid closed-loop technology makes it easier by using Dexcom CGM values to predict glucose levels 30 minutes ahead and automatically adjusts basal insulin every 5 minutes, to help increase time in range.1
NEW Tandem t:slim mobile app*
Give yourself the freedom to more easily manage your diabetes with the Tandem t:slim mobile app*
Freedom to bolus
Bolus from your compatible smartphone*,^ without touching your t:slim X2 insulin pump.
Freedom to be discreet
View pump data on your smartphone as a secondary display for your t:slim X2 insulin pump.
Freedom to be in the know
Automatically upload your pump data to the new Tandem Source platform.††
Check your device’s compatibility here before you download the app.
^ Smart device sold separately.
The t:slim X2 insulin pumps, consumables and Dexcom CGM systems are fully funded by Pharmac for New Zealanders with type 1 diabetes under special authority criteria - prescription may be charged#
To determine if this pump is suitable for you, please consult your healthcare professional. For integration with Dexcom G7, you need to upgrade to the t:slim X2 insulin pump with Control-IQ technology (version 7.7 or later), as the Basal-IQ technology is compatible with Dexcom G6.
After starting with the t:slim X2 insulin pump with Basal-IQ, you can update to Control-IQ technology once you have completed the Control-IQ training module and submitted the Control-IQ update form.
Why choose Tandem?
Easy and simple
- Simplify your routine with zero fingerpricks‡ and no multiple daily injections.
- 97% said it’s easy to use.2
- Slim, sleek, user-friendly colour touchscreen and holds up to 300 units of insulin for added convenience and less frequent cartridge changes.
- 30 min warm-up with Dexcom G7** - When connected to a Dexcom CGM, view glucose readings on the app or pump and use the Dexcom Share feature.
Customisable to your lifestyle
- Freedom to disconnect - For planned or spontaneous activities such as showering, swimming, sports etc.
- Flexible wear locations and a variety of infusion sets to meet your needs.
- Adaptive options to support sleep and exercise activities for tighter control throughout the day and night.
Proven Health Outcomes3-5
- The only automated insulin delivery system featuring Sleep Activity designed to support better overnight glucose control. Giving you the freedom to focus on what truly matters during the day.
- Immediate increase of 11.5% time in range on Day 1.4
- Reduction in diabetes distress such as having a bad night’s sleep and missing work/school due to diabetes.3
Always read the label and use only as directed. Read the warnings available on nzmsdiabetes.co.nz/resources before purchasing. Consult your healthcare professional to see if this product is right for you.
The Tandem t:slim Mobile App is an accessory intended for use as a connected software device that is able to reliably and securely communicate with compatible insulin pumps. The Tandem t:slim mobile app is not intended to control an insulin pump and is not intended as a replacement for the information displayed on your insulin pump. Dosing decisions should not be made based on the secondary display device. The user should follow the instructions on the continuous glucose monitoring system and insulin pump. This secondary device is not intended to replace self-monitoring practices as advised by a physician. Tandem Source is a web application intended to support diabetes management through the display and analysis of information uploaded from Tandem insulin pumps. Tandem t:slim X2 insulin pump with Control-IQ provides continuous delivery of insulin through a subcutaneously applied infusion set. The algorithm will adjust insulin delivery according to the predicted glucose when used with a compatible CGM and Tandem t:slim X2 insulin pump with Basal-IQ provides continuous delivery of insulin through a subcutaneously applied infusion set. The algorithm will stop insulin delivery according to the predictive low glucose when used with a compatible CGM. Dexcom CGM is a continuous glucose monitoring system indicated for the management of (type 1, type 2, gestational) diabetes in people age 2 years and older where self-monitoring of blood glucose (SMBG) is indicated.
§ For terms and conditions, visit https://nzmsdiabetes.co.nz/trading-terms † Dexcom G7 CGM sold separately. Funded Dexcom CGM is available through Pharmac for eligible individuals, for more information visit https://pharmac.govt.nz/. *Bolus delivery from the Tandem t:slim mobile app requires a compatible smartphone model and operating system, software version 7.8.1 onwards on the t:slim X2 insulin pump and additional training. ^Smart device sold separately. To view a list of compatible devices, visit https://nzmsdiabetes.co.nz/mobile-compatibility. †† Uploads to the Tandem Source platform do not take place in real- time and should not be relied upon by healthcare providers, pump users, or caregivers for remote patient monitoring. #Visit pharmac.govt.nz for more information. ‡ If your glucose alerts and readings from Dexcom G7 do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.** Dexcom G7 CGM sold separately. Funded Dexcom CGM is available through Pharmac for eligible individuals, for more information visit https://pharmac.govt.nz/
1. Forlenza GP, Li Z, Buckingham BA, Pinsker JE, et al. 2018;41(10):2155-2161. doi:10.2337/dc18-0771. 2. Kudva YC, Laffel LM, et al. Diabetes Technol Ther. 2021;23(10):673-683. 3. Singh H, et al. Diabetes Technol Ther. 2022; 24(S1): OP094. 4. Beck RW, et al. Diabetes Technol Ther. 2023;25(5):329-342. 5. Breton MD et al. Diabetes Technol Ther. 2021;23(9):601-608.
New Zealand Medical & Scientific Limited, a Dexcom company, 2a Fisher Crescent, Mt Wellington, Auckland, 1060.